Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. (Q36920433)

17 August 2017

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. (English)

1 reference

17 August 2017

Gene B Saylors

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26968534 AND SRC:MED&resulttype=core&format=json

1 June 2020

Stephen E Spurgeon

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26968534 AND SRC:MED&resulttype=core&format=json

1 June 2020

Daniel R Greenwald

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26968534 AND SRC:MED&resulttype=core&format=json

1 June 2020

Susan M O'Brien

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26968534 AND SRC:MED&resulttype=core&format=json

1 June 2020

Andre K D Liem

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26968534 AND SRC:MED&resulttype=core&format=json

1 June 2020

Rosemary E Mclntyre

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26968534 AND SRC:MED&resulttype=core&format=json

1 June 2020

Adarsh Joshi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26968534 AND SRC:MED&resulttype=core&format=json

1 June 2020

Esteban Abella-Dominicis

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26968534 AND SRC:MED&resulttype=core&format=json

1 June 2020

Michael J Hawkins

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26968534 AND SRC:MED&resulttype=core&format=json

1 June 2020

Anita Reddy

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26968534 AND SRC:MED&resulttype=core&format=json

1 June 2020

Julie Di Paolo

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26968534 AND SRC:MED&resulttype=core&format=json

1 June 2020

Hank Lee

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26968534 AND SRC:MED&resulttype=core&format=json

1 June 2020

Joyce He

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26968534 AND SRC:MED&resulttype=core&format=json

1 June 2020

Jing Hu

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26968534 AND SRC:MED&resulttype=core&format=json

1 June 2020

Lyndah K Dreiling

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26968534 AND SRC:MED&resulttype=core&format=json

1 June 2020

Jonathan W Friedberg

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26968534 AND SRC:MED&resulttype=core&format=json

1 June 2020

language of work or name

English

0 references

publication date

11 March 2016

1 reference

17 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26968534 AND SRC:MED&resulttype=core&format=json

1 June 2020

volume

127

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26968534 AND SRC:MED&resulttype=core&format=json

1 June 2020

issue

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26968534 AND SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

2411-2415

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26968534 AND SRC:MED&resulttype=core&format=json

An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia

1 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874222

Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874222

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874222

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874222

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874222

Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874222

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874222

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874222

Sirolimus-associated pulmonary toxicity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874222

Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874222

Interferon-gamma is necessary for the expression of hypersensitivity pneumonitis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874222

Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874222

The TSC-mTOR signaling pathway regulates the innate inflammatory response

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874222

Revised response criteria for malignant lymphoma

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874222

Early Variations of Circulating Interleukin-6 and Interleukin-10 Levels During Thoracic Radiotherapy Are Predictive for Radiation Pneumonitis

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874222

Hypersensitivity pneumonitis

4 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26968534

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Circulating IL-6 as a predictor of radiation pneumonitis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26968534

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1182/BLOOD-2015-12-683516

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26968534 AND SRC:MED&resulttype=core&format=json

1 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26968534 AND SRC:MED&resulttype=core&format=json

1 June 2020

PubMed publication ID

26968534

1 reference